Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus GLYCOPYRROLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus GLYCOPYRROLATE.
ANTRENYL vs GLYCOPYRROLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Glycopyrrolate is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors in the autonomic nervous system, thereby reducing salivary, gastric, and bronchial secretions. It also exhibits antispasmodic effects on gastrointestinal smooth muscle.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
1-2 mg orally 2-3 times daily; maximum 8 mg/day. For parenteral use: 0.1-0.2 mg IV/IM every 4-6 hours as needed.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life: 0.6-1.2 hours (IM/IV), with prolonged duration in elderly and renal impairment.
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Primarily renal excretion of unchanged drug (85-90%) with biliary/fecal elimination accounting for <10%.
Category C
Category C
Anticholinergic
Anticholinergic